Patents Assigned to Green Cross Corporation
-
Publication number: 20210213109Abstract: A pharmaceutical composition including an iduronate-2-sulfatase beta (IDS-?) may be administered into the cerebral lateral ventricle once every four weeks to treat Hunter syndrome in a subject. Compared to a single administration of the same dose of an active substance, due to repeated administrations over a long period of time, the administration exhibits superior effects in treating Hunter syndrome, and further has the following effects which cannot be anticipated from the result of a single administration: treating or restoring a damaged brain structure; and substantially treating or improving brain functions, particularly, improving memory and learning.Type: ApplicationFiled: May 30, 2019Publication date: July 15, 2021Applicants: MEDIGENEBIO CORPORATION, GREEN CROSS CORPORATIONInventor: Jae Yeon YEO
-
Patent number: 11052135Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of Idursulfase-beta, a human recombinant iduronate-2-sulfatase protein, for effective treatment of Hunter Syndrome. The compositions and methods provided by the present invention effectively reduce symptoms not only in brain and spinal cord but also in peripheral tissues including heart, liver, spleen, lung, and kidney.Type: GrantFiled: December 21, 2016Date of Patent: July 6, 2021Assignees: GREEN CROSS CORPORATION, MEDIGENEBIO CORPORATIONInventors: Torayuki Okuyama, Thong-Gyu Jin, Han-Yeul Byun, Jin-Wook Seo, Byoung-Ju Lee, Yong-Chul Kim, In-Young Jang, Kyuhyun Lee
-
Patent number: 10918717Abstract: The present invention provides a pharmaceutical formulation comprising an anti-epidermal growth factor receptor (EGFR) antibody. The pharmaceutical formulation has low turbidity, without showing aggregation or particle formation, even under accelerated conditions, and exhibits good stability. Therefore, the pharmaceutical formulation can be effectively used for the treatment of disorders such as cancer.Type: GrantFiled: January 15, 2016Date of Patent: February 16, 2021Assignee: GREEN CROSS CORPORATIONInventors: Yong Woon Choi, Yoo Hoon Kim, Jungsub Choi
-
Patent number: 10889574Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.Type: GrantFiled: August 30, 2019Date of Patent: January 12, 2021Assignees: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATIONInventors: Hee-kyoon Yoon, Se-Hwan Park, Ji-sung Yoon, Soongyu Choi, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Kwang-Seop Song, Min Ju Kim, So Ok Park
-
Patent number: 10851175Abstract: The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.Type: GrantFiled: September 23, 2016Date of Patent: December 1, 2020Assignees: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATIONInventors: Dong-Sik Kim, Eun Jung Song, Mijung Lee, Eun-Hee Lee, Miyoung Oh, Jae Chan Park, Kisu Kim, Sujeong Kim, Hyung-Kwon Lim, Kyuhyun Lee, Jongwha Won, Soongyu Choi, Young Seoub Park
-
Publication number: 20200361985Abstract: A method for purification of a sulfatase using metal chelating chromatography without using tags such as His-tag, etc. is disclosed. An embodiment provides a method for purifying a sulfatase including the steps of: (a) providing a sulfatase-containing solution comprising one or a plurality of impurities; (b) performing a first chromatographic separation of the sulfatase-containing solution using a metal affinity chromatography resin; (c) performing a second chromatographic separation using a cation exchange chromatography resin; and (d) performing a final chromatographic separation using an anion exchange chromatography resin, wherein the impurities are removed thereby.Type: ApplicationFiled: August 31, 2017Publication date: November 19, 2020Applicant: GREEN CROSS CORPORATIONInventors: Denis FESHIN, Byung Hyun PARK, Yong Won SHIN
-
Publication number: 20200299395Abstract: Provided according to an embodiment of the present invention is an antibody that binds specifically to B-cell maturation antigen (BCMA) and comprises a heavy chain variable domain (VH domain) composed of a sequence having a homology of 80% or higher with any one of the amino acid sequences of SEQ ID NOS: 1 to 20, or a fragment thereof.Type: ApplicationFiled: September 21, 2018Publication date: September 24, 2020Applicants: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATIONInventors: Hye-Ji CHOI, Jae-Chan PARK, Hyung-Kwon LIM
-
Publication number: 20200268857Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of Idursulfase-beta, a human recombinant iduronate-2-sulfatase protein, for effective treatment of Hunter Syndrome. The compositions and methods provided by the present invention effectively reduce symptoms not only in brain and spinal cord but also in peripheral tissues including heart, liver, spleen, lung, and kidney.Type: ApplicationFiled: December 21, 2016Publication date: August 27, 2020Applicants: GREEN CROSS CORPORATION, MediGeneBio CorporationInventors: Torayuki OKUYAMA, Thong-Gyu JIN, Han-Yeul BYUN, Jin-Wook SEO, Byoung-Ju LEE, Yong-Chul KIM, In-Young JANG, Kyuhyun LEE
-
Publication number: 20200262928Abstract: The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment.Type: ApplicationFiled: October 22, 2018Publication date: August 20, 2020Applicants: GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Ki Su KIM, Jung Hong JEONG, Dong Sik KIM, Yang Mi LIM, Yong Yea PARK, Hyung Kwon LIM, Jong Wha WON
-
Patent number: 10640496Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.Type: GrantFiled: June 15, 2017Date of Patent: May 5, 2020Assignees: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATIONInventors: Hee-kyoon Yoon, Se-Hwan Park, Ji-sung Yoon, Soongyu Choi, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Kwang-Seop Song, Min Ju Kim, So Ok Park
-
Publication number: 20200109196Abstract: The present invention provides anti-CEACAM1 antibodies with improved binding abilities specific to CEACAM1, and a use thereof. Anti-CEACAM1 antibodies according to the present invention exhibit superior binding abilities specific to CEACAM1, and also activate the anti-cancer immune functions of cytotoxic T cells and natural killer cells, and thus, each one of them can be effectively used as an anti-cancer agent and a composition for treating cancer.Type: ApplicationFiled: March 23, 2018Publication date: April 9, 2020Applicants: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATIONInventors: So-Young EUN, Miyoung OH, Hye-Young PARK, Mijung LEE, Aerin YOON, Hye In YUM, Hyemi NAM, Eunhee LEE, Jongwha WON
-
Publication number: 20200093899Abstract: A Hunter syndrome therapeutic agent contains a first composition to be intravenously injected and a second composition to be subcutaneously injected. The agent can reduce the number of visits to the hospital by patients with Hunter syndrome to twice a month or less. It maintains a medicinal effect equivalent to or greater than that of a conventional once-a-week IV injection, increases drug-taking compliance of patients in comparison to conventional therapeutic agents and treatment methods, and enables enhanced patient welfare and convenience.Type: ApplicationFiled: November 27, 2019Publication date: March 26, 2020Applicants: GREEN CROSS CORPORATION, MEDIGENEBIO CORPORATIONInventors: Jin-Kyung LEE, Han-Yeul BYUN, Myung-Eun JUNG, Kyu-Hyun LEE
-
Patent number: 10561713Abstract: A Hunter syndrome therapeutic agent contains a first composition to be intravenously injected and a second composition to be subcutaneously injected. The agent can reduce the number of visits to the hospital by patients with Hunter syndrome to twice a month or less. It maintains a medicinal effect equivalent to or greater than that of a conventional once-a-week IV injection, increases drug-taking compliance of patients in comparison to conventional therapeutic agents and treatment methods, and enables enhanced patient welfare and convenience.Type: GrantFiled: July 4, 2016Date of Patent: February 18, 2020Assignees: GREEN CROSS CORPORATION, MEDIGENEBIO CORPORATIONInventors: Jin-Kyung Lee, Han-Yeul Byun, Myung-Eun Jung, Kyu-Hyun Lee
-
Publication number: 20190382390Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.Type: ApplicationFiled: August 30, 2019Publication date: December 19, 2019Applicants: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATIONInventors: Hee-kyoon YOON, Se-Hwan PARK, Ji-sung YOON, Soongyu CHOI, Hee Jeong SEO, Eun-Jung PARK, Younggyu KONG, Kwang-Seop SONG, Min Ju KIM, So Ok PARK
-
Patent number: 10444246Abstract: Provided are a kit for measuring a titer of a human antibody, a humanized antibody, or a human Fc-fusion protein in human plasma or serum, and a method for measuring a titer of a human Fc-containing protein in human plasma or serum using the same, and more specifically, a kit for measuring a titer of human Fc-containing protein in human plasma or serum, the kit including a diluent for sample, a diluent for conjugate, and a cleansing solution and being used in analysis through an indirect enzyme-linked immunosorbent assay (indirect ELISA), and a method for measuring a titer of human Fc-containing protein in human plasma or serum using the same.Type: GrantFiled: September 30, 2015Date of Patent: October 15, 2019Assignee: GREEN CROSS CORPORATIONInventors: Yong Won Shin, Juho Lee, Jeong-Ae Lim, Ki Hwan Chang, Min-Soo Kim
-
Publication number: 20190169174Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.Type: ApplicationFiled: June 15, 2017Publication date: June 6, 2019Applicants: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATIONInventors: Hee-kyoon YOON, Se-Hwan PARK, Ji-Sung YOON, Soongyu CHOI, Hee Jeong SEO, Eun-Jung PARK, Younggyu KONG, Kwang-Seop SONG, Min Ju KIM, So Ok PARK
-
Publication number: 20190153117Abstract: Disclosed are epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-?, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.Type: ApplicationFiled: January 28, 2019Publication date: May 23, 2019Applicants: GREEN CROSS CORPORATION, MOGAM BIOTECHNOLOGY RESEARCH INSTITUTEInventors: Se-Ho Kim, Kwang-Won Hong, Ki-Hwan Chang, Min-Soo Kim, Mi-Jung Lee, Jong-Hwa Won, Min-Kyu Hur, Hyun-Soo Cho, Ji-Ho Yoo
-
Pyrazole derivatives as TNIK, IKK? and TBK1 inhibitor and pharmaceutical composition comprising same
Patent number: 10294207Abstract: Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.Type: GrantFiled: March 29, 2016Date of Patent: May 21, 2019Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kisoo Park, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Ickhwan Son, Sang-ho Ma, Kwang-Seop Song, Min Ju Kim, So Ok Park, Man-Young Cha, Mi-Soon Kim, Sang Mi Kang, Dong Hyuk Jang, Jangwon Hong -
Publication number: 20190119388Abstract: The present invention provides a pharmaceutical composition for inhibiting the metastasis of cancer, comprising, as an active ingredient, an antibody that specifically binds to an epidermal growth factor receptor, and a method for inhibiting the metastasis of cancer using the composition. The composition or the method is effective in inhibiting the invasion of various gastric cancer cell lines induced by EGFR ligands. Therefore, the pharmaceutical composition can be usefully used for inhibiting the metastasis of cancer.Type: ApplicationFiled: April 27, 2016Publication date: April 25, 2019Applicants: GREEN CROSS CORPORATION, MOGAM INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Jong-hwa WON, Yangmi LIM, Min-Kyu HUR
-
Patent number: 10239873Abstract: Provided are 7-azaindole or 4,7-diazaindole derivatives as an IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.Type: GrantFiled: March 24, 2016Date of Patent: March 26, 2019Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kwang-Seop Song, Hee Jeong Seo, Sang-ho Ma, Eun-Jung Park, Younggyu Kong, So Ok Park, Kisoo Park, Ickhwan Son, Min Ju Kim, Man-Young Cha, Mi-Soon Kim, Sang Mi Kang, Dong Hyuk Jang, Jangwon Hong